Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says

Jefferies highlights Viridian Therapeutics' (VRDN) VRDN-008 as a potential best-in-class FcRn inhibitor, with an extended half-life supporting eight-week dosing. Phase I results showed a 74% peak IgG reduction sustained for eight weeks. The company plans to start a registrational study in gMG in mid-2027, with potential approval by 2031. Jefferies maintains a $35 price target, excluding contributions from VRDN's broader pipeline.

Original reporting
Published Nov 9, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says — source image
Decision brief

The 30-second read

$VRDNBullishMed
01

Why it matters

The Phase I results provide a tangible efficacy signal and a differentiated dosing regimen, supporting a higher valuation outlook.

02

Market read

Positive early data may trigger buying interest in VRDN and influence peer valuations in the FcRn inhibitor niche.

03

What to watch

Potential competition from argenx's ARGX‑213 and uncertainty around regulatory timelines.

Relevance 8/10Novelty 8/10Timing: immediate

Background

Jefferies highlights VRDN-008 as a best‑in‑class FcRn inhibitor with an eight‑week dosing schedule, targeting generalized myasthenia gravis first.

Company-level read

Ticker impact

$VRDNBullishHigh confidence
Context

Jefferies reports positive Phase I data for VRDN-008, showing a 15‑18 day half‑life and ~74% IgG reduction, marking the first public disclosure of these results.

Expected impact

likely upward pressure as the market prices in the extended half‑life advantage.

Evidence & confidence

Phase I results are material for a biotech and the broker assigns a $35 price target, indicating belief in significant upside.

Market effects

The data may boost the broader FcRn inhibitor space, prompting re‑valuation of peers such as argenx.

US biotech sector could see modest gains as investors reassess pipeline timelines.

Limited to biotech investors; no broad market impact.

Counterpoint

The on‑body injector delivery could limit adoption, tempering upside.

Key entities

  • Viridian Therapeutics

    NASDAQ‑listed biotech developing VRDN‑008.

  • Jefferies

    Equity research firm issuing the upgrade and price target.

Related articles

$VRDNMedAI 8/10

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

Viridian Therapeutics, Inc.\DE (VRDN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing - VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 weeks after sub

$VRDNHighAI 8/10

Viridian reports phase 1 results for VRDN-008 autoimmune drug

Viridian Therapeutics (VRDN) reported phase 1 trial results for VRDN-008, showing a 74% reduction in IgG and a half-life of 15-18 days. No serious adverse events were observed. The company plans to start pivotal trials in 2027, targeting myasthenia gravis first. VRDN-008 will be administered using Enable Injections’ enFuse device, licensed exclusively by Viridian.

$VRDNMed

Viridian (VRDN) Q3 2026 Earnings Call Transcript

Viridian Therapeutics (VRDN) reported Q3 2026 earnings, with $24.7M in net product revenue from Lumvoa, its newly approved thyroid eye disease treatment. The company has over 100 patients on therapy and $955.2M in cash. Net loss was $101.2M, up from $34.6M last year. Management expects to submit a Biologics License Application for subcutaneous elegrobart in Q1 2027 and initiate a Phase I trial for VRDN-292 in Q4 2026.